ENORAMA PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.57 SEK | +7.08% |
|
-1.15% | -17.10% |
| 05-22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 311.6 | 224 | 195.5 | 171 | 28.05 | 114.5 |
| Enterprise Value (EV) 1 | 296.7 | 209.4 | 196.4 | 162.6 | 25.82 | 108.8 |
| P/E ratio | -19.1 x | -9.41 x | -7.85 x | -4.97 x | -0.68 x | -1.92 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 26 x | 21.5 x | 43.7 x | 13.4 x | 4.1 x | 84.3 x |
| EV / Revenue | 24.8 x | 20.1 x | 44 x | 12.7 x | 3.77 x | 80.1 x |
| EV / EBITDA | -19.2 x | -9.22 x | -8.66 x | -6.19 x | -0.63 x | -2.64 x |
| EV / FCF | -32.9 x | -9.02 x | -11.8 x | -6.03 x | -1.32 x | -4.68 x |
| FCF Yield | -3.04% | -11.1% | -8.44% | -16.6% | -75.6% | -21.4% |
| Price to Book | 18.3 x | 31.2 x | 110 x | 8.01 x | 1.08 x | 6.49 x |
| Nbr of stocks (in thousands) | 5,299 | 5,531 | 5,905 | 7,686 | 7,686 | 36,925 |
| Reference price 2 | 58.80 | 40.50 | 33.10 | 22.25 | 3.650 | 3.100 |
| Announcement Date | 19-04-15 | 20-04-15 | 21-04-14 | 22-04-13 | 23-06-09 | 24-05-05 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 11.98 | 10.43 | 4.469 | 12.8 | 6.847 | 1.358 |
| EBITDA 1 | -15.49 | -22.72 | -22.69 | -26.28 | -41.3 | -41.15 |
| EBIT 1 | -15.49 | -22.88 | -23.01 | -26.94 | -41.96 | -41.82 |
| Operating Margin | -129.33% | -219.23% | -514.9% | -210.49% | -612.9% | -3,079.82% |
| Earnings before Tax (EBT) 1 | -16.34 | -23.8 | -23.46 | -27.74 | -42.03 | -44.61 |
| Net income 1 | -16.34 | -23.8 | -23.46 | -27.74 | -42.03 | -44.61 |
| Net margin | -136.4% | -228.07% | -524.86% | -216.75% | -613.85% | -3,285.2% |
| EPS 2 | -3.084 | -4.302 | -4.217 | -4.475 | -5.371 | -1.611 |
| Free Cash Flow 1 | -9.004 | -23.21 | -16.59 | -26.98 | -19.52 | -23.22 |
| FCF margin | -75.17% | -222.43% | -371.18% | -210.8% | -285.07% | -1,709.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-04-15 | 20-04-15 | 21-04-14 | 22-04-13 | 23-06-09 | 24-05-05 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.98 | - | - | - |
| Net Cash position 1 | 14.9 | 14.6 | - | 8.41 | 2.23 | 5.72 |
| Leverage (Debt/EBITDA) | - | - | -0.043 x | - | - | - |
| Free Cash Flow 1 | -9 | -23.2 | -16.6 | -27 | -19.5 | -23.2 |
| ROE (net income / shareholders' equity) | -134% | -197% | -524% | -240% | -159% | -175% |
| ROA (Net income/ Total Assets) | -35.7% | -35.1% | -34.5% | -36.7% | -52.6% | -62.9% |
| Assets 1 | 45.83 | 67.76 | 68.08 | 75.66 | 79.85 | 70.92 |
| Book Value Per Share 2 | 3.210 | 1.300 | 0.3000 | 2.780 | 3.370 | 0.4800 |
| Cash Flow per Share 2 | 3.100 | 2.640 | 0.8000 | 1.590 | 0.4400 | 0.1500 |
| Capex 1 | 0.45 | 1.35 | 1.51 | 0.06 | - | - |
| Capex / Sales | 3.74% | 12.91% | 33.86% | 0.47% | - | - |
| Announcement Date | 19-04-15 | 20-04-15 | 21-04-14 | 22-04-13 | 23-06-09 | 24-05-05 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.10% | 9.4M | |
| +19.42% | 43.78B | |
| +16.77% | 21.56B | |
| +21.10% | 15.64B | |
| +25.15% | 15.25B | |
| +55.77% | 13.02B | |
| -0.05% | 6.79B | |
| -16.49% | 6.36B | |
| +19.77% | 5.81B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- ERMA Stock
- Financials Enorama Pharma AB
